CEO: Nicola Thompson

Advent Contact: Raj Parekh

A new approach to protein degradation

Amphista Therapeutics are developing drugs to bring life-changing medicines to patients. Powered by transformational science, they are advancing beyond traditional degrader approaches. Amphista is using targeted protein degradation (TPD) to hijacks the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression. Their approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Advent founded and seeded Amphista in 2018.

Amphista Therapeutics raises $7.5m Series A round